Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes

被引:70
作者
Stasi, R
Abruzzese, E
Lanzetta, G
Terzoli, E
Amadori, S
机构
[1] Regina Apostolorum Hosp, Dept Med Sci, I-00041 Albano Laziale, Italy
[2] Univ Roma Tor Vergata, Dept Hematol, S Eugenio Hosp, Rome, Italy
[3] Regina Elena Inst Canc Res, Dept Complementary Oncol, IFO, Rome, Italy
[4] INI, Dept Oncol, Grottaferrata, Italy
关键词
anemia; darbepoetin alfa; erythropoietin; myelodysplastic syndrome; predictive factors;
D O I
10.1093/annonc/mdi400
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The hematological and quality of life (QoL) changes associated with darbepoetin alfa (DA) therapy were assessed in anemic patients with previously untreated low- and intermediate-1-risk myelodysplastic syndrome (MDS). Patients and methods: Fifty-three patients received DA administered subcutaneously once a week for 24 weeks. Treatment was initiated at 150 mu g fixed dose and was doubled if after the first 12 weeks there was no or suboptimal erythroid response. Results: The final response rate was 24/53 (45%), with 21 major and three minor responses. Most of the responses (21/24; 87.5%) were obtained at the dose of 150 mu g. With a median follow-up of 9.4 months, 17 patients maintain their response. Treatment was well tolerated with no relevant side-effects. MDS progression was observed in one case. Increases in hemoglobin levels were positively correlated with improved QoL scores using both the linear analog scale assessment (energy level, r = 0.429, P = 0.036; daily activities, r = 0.653, P < 0.001; overall well-being, r = 0.457, P = 0.024) and the Functional Assessment of Cancer Therapy-Anemia questionnaire (r = 0.247, P = 0.025). In multivariate analysis, only low levels (< 200 IU/l) of endogenous erythropoietin predicted response to DA therapy. Conclusions: DA is an active, safe and well tolerated treatment for anemia in a substantial proportion of patients with low- and intermediate-1-risk MDS, and has a positive impact on the patients' QoL.
引用
收藏
页码:1921 / 1927
页数:7
相关论文
共 27 条
  • [1] Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes:: a randomized, controlled trial
    Casadevall, N
    Durieux, P
    Dubois, S
    Hemery, F
    Lepage, E
    Quarré, MC
    Damaj, G
    Giraudier, S
    Guerci, A
    Laurent, G
    Dombret, H
    Chomienne, C
    Ribrag, V
    Stamatoullas, A
    Marie, JP
    Vekhoff, A
    Maloisel, F
    Navarro, R
    Dreyfus, F
    Fenaux, P
    [J]. BLOOD, 2004, 104 (02) : 321 - 327
  • [2] Cella D, 1997, SEMIN HEMATOL, V34, P13
  • [3] Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes
    Cella, D
    Dobrez, D
    Glaspy, J
    [J]. ANNALS OF ONCOLOGY, 2003, 14 (04) : 511 - 519
  • [4] Cheson BD, 2000, BLOOD, V96, P3671
  • [5] ON THE RECEIVING END .2. LINEAR ANALOG SELF-ASSESSMENT (LASA) IN EVALUATION OF ASPECTS OF THE QUALITY OF LIFE OF CANCER-PATIENTS RECEIVING THERAPY
    COATES, A
    DILLENBECK, CF
    MCNEIL, DR
    KAYE, SB
    SIMS, K
    FOX, RM
    WOODS, RL
    MILTON, GW
    SOLOMON, J
    TATTERSALL, MHN
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1983, 19 (11): : 1633 - 1637
  • [6] Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin
    Egrie, JC
    Dwyer, E
    Browne, JK
    Hitz, A
    Lykos, MA
    [J]. EXPERIMENTAL HEMATOLOGY, 2003, 31 (04) : 290 - 299
  • [7] Gore Steven, 2004, Cancer Control, V11, P3
  • [8] International scoring system for evaluating prognosis in myelodysplastic syndromes
    Greenberg, P
    Cox, C
    LeBeau, MM
    Fenaux, P
    Morel, P
    Sanz, G
    Sanz, M
    Vallespi, T
    Hamblin, T
    Oscier, D
    Ohyashiki, K
    Toyama, K
    Aul, C
    Mufti, G
    Bennett, J
    [J]. BLOOD, 1997, 89 (06) : 2079 - 2088
  • [9] Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment
    Greenberg, PL
    [J]. LEUKEMIA RESEARCH, 1998, 22 (12) : 1123 - 1136
  • [10] Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies:: a randomized, double-blind, placebo-controlled study
    Hedenus, M
    Adriansson, M
    San Miguel, J
    Kramer, MHH
    Schipperus, MR
    Juvonen, E
    Taylor, K
    Belch, A
    Altés, A
    Martinelli, G
    Watson, D
    Matcham, J
    Rossi, G
    Littlewood, TJ
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (03) : 394 - 403